These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32355042)

  • 1. Structure of the N-terminal domain of ClpC1 in complex with the antituberculosis natural product ecumicin reveals unique binding interactions.
    Wolf NM; Lee H; Zagal D; Nam JW; Oh DC; Lee H; Suh JW; Pauli GF; Cho S; Abad-Zapatero C
    Acta Crystallogr D Struct Biol; 2020 May; 76(Pt 5):458-471. PubMed ID: 32355042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-Resolution Structure of ClpC1-Rufomycin and Ligand Binding Studies Provide a Framework to Design and Optimize Anti-Tuberculosis Leads.
    Wolf NM; Lee H; Choules MP; Pauli GF; Phansalkar R; Anderson JR; Gao W; Ren J; Santarsiero BD; Lee H; Cheng J; Jin YY; Ho NA; Duc NM; Suh JW; Abad-Zapatero C; Cho S
    ACS Infect Dis; 2019 Jun; 5(6):829-840. PubMed ID: 30990022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of the inhibitory mechanism of ecumicin and rufomycin 4-7 on the proteolytic activity of Mycobacterium tuberculosis ClpC1/ClpP1/ClpP2 complex.
    Hong J; Duc NM; Jeong BC; Cho S; Shetye G; Cao J; Lee H; Jeong C; Lee H; Suh JW
    Tuberculosis (Edinb); 2023 Jan; 138():102298. PubMed ID: 36580851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation analysis of the interactions between Mycobacterium tuberculosis caseinolytic protease C1 (ClpC1) and ecumicin.
    Jung IP; Ha NR; Kim AR; Kim SH; Yoon MY
    Int J Biol Macromol; 2017 Aug; 101():348-357. PubMed ID: 28342755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crystal structure of the N-terminal domain of MtClpC1 in complex with the anti-mycobacterial natural peptide Lassomycin.
    Jagdev MK; Tompa DR; Ling LL; Peoples AJ; Dandapat J; Mohapatra C; Lewis K; Vasudevan D
    Int J Biol Macromol; 2023 Dec; 253(Pt 2):126771. PubMed ID: 37683752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rufomycin Targets ClpC1 Proteolysis in Mycobacterium tuberculosis and M. abscessus.
    Choules MP; Wolf NM; Lee H; Anderson JR; Grzelak EM; Wang Y; Ma R; Gao W; McAlpine JB; Jin YY; Cheng J; Lee H; Suh JW; Duc NM; Paik S; Choe JH; Jo EK; Chang CL; Lee JS; Jaki BU; Pauli GF; Franzblau SG; Cho S
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30602512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antibiotic cyclomarin blocks arginine-phosphate-induced millisecond dynamics in the N-terminal domain of ClpC1 from
    Weinhäupl K; Brennich M; Kazmaier U; Lelievre J; Ballell L; Goldberg A; Schanda P; Fraga H
    J Biol Chem; 2018 Jun; 293(22):8379-8393. PubMed ID: 29632076
    [No Abstract]   [Full Text] [Related]  

  • 8. Structure of the drug target ClpC1 unfoldase in action provides insights on antibiotic mechanism of action.
    Weinhäupl K; Gragera M; Bueno-Carrasco MT; Arranz R; Krandor O; Akopian T; Soares R; Rubin E; Felix J; Fraga H
    J Biol Chem; 2022 Nov; 298(11):102553. PubMed ID: 36208775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cyclic peptide ecumicin targeting ClpC1 is active against Mycobacterium tuberculosis in vivo.
    Gao W; Kim JY; Anderson JR; Akopian T; Hong S; Jin YY; Kandror O; Kim JW; Lee IA; Lee SY; McAlpine JB; Mulugeta S; Sunoqrot S; Wang Y; Yang SH; Yoon TM; Goldberg AL; Pauli GF; Suh JW; Franzblau SG; Cho S
    Antimicrob Agents Chemother; 2015 Feb; 59(2):880-9. PubMed ID: 25421483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis of mycobacterial inhibition by cyclomarin A.
    Vasudevan D; Rao SP; Noble CG
    J Biol Chem; 2013 Oct; 288(43):30883-91. PubMed ID: 24022489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Mycobacterium tuberculosis ClpP1P2 Protease Interacts Asymmetrically with Its ATPase Partners ClpX and ClpC1.
    Leodolter J; Warweg J; Weber-Ban E
    PLoS One; 2015; 10(5):e0125345. PubMed ID: 25933022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The natural product cyclomarin kills Mycobacterium tuberculosis by targeting the ClpC1 subunit of the caseinolytic protease.
    Schmitt EK; Riwanto M; Sambandamurthy V; Roggo S; Miault C; Zwingelstein C; Krastel P; Noble C; Beer D; Rao SP; Au M; Niyomrattanakit P; Lim V; Zheng J; Jeffery D; Pethe K; Camacho LR
    Angew Chem Int Ed Engl; 2011 Jun; 50(26):5889-91. PubMed ID: 21563281
    [No Abstract]   [Full Text] [Related]  

  • 13. Potent Bactericidal Antimycobacterials Targeting the Chaperone ClpC1 Based on the Depsipeptide Natural Products Ecumicin and Ohmyungsamycin A.
    Hawkins PME; Hoi DM; Cheung CY; Wang T; Quan D; Sasi VM; Liu DY; Linington RG; Jackson CJ; Oehlers SH; Cook GM; Britton WJ; Clausen T; Payne RJ
    J Med Chem; 2022 Mar; 65(6):4893-4908. PubMed ID: 35293761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The C-terminus of ClpC1 of Mycobacterium tuberculosis is crucial for its oligomerization and function.
    Bajaj D; Batra JK
    PLoS One; 2012; 7(12):e51261. PubMed ID: 23284674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tuberculosis lead molecules from natural products targeting Mycobacterium tuberculosis ClpC1.
    Lee H; Suh JW
    J Ind Microbiol Biotechnol; 2016 Mar; 43(2-3):205-12. PubMed ID: 26586403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The unfoldase ClpC1 of
    Lunge A; Gupta R; Choudhary E; Agarwal N
    J Biol Chem; 2020 Jul; 295(28):9455-9473. PubMed ID: 32409584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total Synthesis and Biological Evaluation of Modified Ilamycin Derivatives.
    Greve J; Mogk A; Kazmaier U
    Mar Drugs; 2022 Oct; 20(10):. PubMed ID: 36286456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosynthetic Interrogation of Soil Metagenomes Reveals Metamarin, an Uncommon Cyclomarin Congener with Activity against
    Li L; MacIntyre LW; Ali T; Russo R; Koirala B; Hernandez Y; Brady SF
    J Nat Prod; 2021 Apr; 84(4):1056-1066. PubMed ID: 33621083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycobacterium tuberculosis ClpC1: characterization and role of the N-terminal domain in its function.
    Kar NP; Sikriwal D; Rath P; Choudhary RK; Batra JK
    FEBS J; 2008 Dec; 275(24):6149-58. PubMed ID: 19016865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clp-targeting BacPROTACs impair mycobacterial proteostasis and survival.
    Hoi DM; Junker S; Junk L; Schwechel K; Fischel K; Podlesainski D; Hawkins PME; van Geelen L; Kaschani F; Leodolter J; Morreale FE; Kleine S; Guha S; Rumpel K; Schmiedel VM; Weinstabl H; Meinhart A; Payne RJ; Kaiser M; Hartl M; Boehmelt G; Kazmaier U; Kalscheuer R; Clausen T
    Cell; 2023 May; 186(10):2176-2192.e22. PubMed ID: 37137307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.